Pharmafile Logo
Pharmafocus logo
Advanced Search

migraine

Showing 12 posts of 42 posts found.

allergan

Allergan unveils second bout of Phase 3 success in migraine

April 30, 2018
Research and Development, Sales and Marketing Allergan, migraine, pharma, ubrogepant

Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …

News
amgen_flag

Amgen and Novartis’ Aimovig shines in migraine at Phase 3

April 18, 2018
Research and Development Aimovig, Amgen, Novartis, migraine, pharma

Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …

News
headache

Reaction mixed to Biohaven’s migraine drug results

March 27, 2018
Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical

Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …

News
aaa

Insider Interview: Allergan’s R&D Chief on plans to be “the headache company”

February 22, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, David Nicholson, Insider Interview, migraine, pharma

Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the …

Feature
headache

Novartis’ Phase 3 migraine data could revolutionise treatment

November 30, 2017
Research and Development CGRP, Novartis Amgen, biotech, drugs, migraine, pharma, pharmaceutical

Descriptions of treatments as ‘revolutionary’ or ‘ground-breaking’ are ten a penny in the pharmaceutical industry, very rarely do such treatments …

News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …

News

Amgen, Novartis migraine drug meets primary endpoint in Phase II study

June 9, 2016
Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine

A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …

News
Teva image

Teva and Heptares enter $400m agreement for small-molecule migraine treatment

November 25, 2015
Research and Development Heptares, Teva, collaboration, migraine

Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …

News
Alzheimer's brain

Amgen and Novartis partner on Alzheimer’s and migraine treatments

September 2, 2015
Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …

News
teva_copy

Teva lifted by positive migraine drug results

May 15, 2015
Sales and Marketing TEV-48125, Teva, headaches, migraine

Patients who take either dose of Teva’s investigational treatment for chronic migraine improve more than those taking a placebo according …

News

Allergan in $958m neurology deal

January 25, 2013
Sales and Marketing Allergan, CNS, MAP Pharmaceuticals, migraine

Allergan is to pay $958m for MAP Pharmaceuticals in a deal which sees both companies hoping to reap the benefits …

News
Pfizer's website

Pfizer launches ‘Campaign Against Migraine’ website

June 18, 2012
Medical Communications Botox, Pfizer, Relpax, digital, migraine

Pfizer has launched a new website called ‘Campaign Against Migraine’ to help migraine sufferers in the US learn more about …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026